YSOPIA Bioscience leading biotech in the development of innovative microbiome-based therapies

YSOPIA Bioscience, a clinical-stage biotech leading next-generation microbiome-based living biotherapies

more +
lnc
Our Story

Our team is committed to deliver groundbreaking therapeutic solutions to patients with high needs

more +
lnc
therapeutic solutions
lnc

YSOPIA Bioscience is the 1st company to harness the therapeutic potential of Christensenella

Our leadership

Fabrice GUEZ
Fabrice GUEZ CEO & CFO
Fabrice GUEZ
CEO & CFO

Putting people first

Fabrice is an accomplished executive with more than two decades of experience within biotech environment and pharmaceutical SMEs. He co-founded YSOPIA Bioscience.

Sandrine CLAUS
Sandrine CLAUS CSO
Sandrine CLAUS
CSO

Beyond the state of the art

Sandrine joined YSOPIA Bioscience in 2017 as Chief Scientific Officer. She previously served as Associate Professor in Integrative Metabolism at the University of Reading’s department of Food and Nutritional Sciences.

Frédéric Elustondo
Frédéric Elustondo Senior Director of Operations
Frédéric Elustondo
Senior Director of Operations

Execute the right project

Frederic’s expertise focuses on project management and innovation in the different positions he held in the hospital & health care industry.

 
Wilfrid Mazier
Wilfrid Mazier Director of R&D
Wilfrid Mazier
Director of R&D

Translating science into innovations

Wilfrid is an experienced scientist and manager who led several R&D programs in health and nutrition. He has been part of many translational research programs in a wide diversity of specialized fields like obesity, metabolism, mood, or mental disabilities. 

Leveraging partnership for success more +
ICAN
LuinaBio
INRA
Quay Pharma
Cornel University
Bioaster
lnc
Microbiome & us
News
Apr 8, 2022
YSOPIA Bioscience Announces the Appointment of Dr. Jean-Pierre Lehner as New Chairman of the Board of Directors |...
> more
Apr 8, 2022
YSOPIA Bioscience annonce la nomination du Dr. Jean-Pierre Lehner comme nouveau Président du Conseil d’Administration...
> more
Press / Media
Apr 14, 2022
     Fabrice Guez, CEO et CFO d’Ysopia Bioscience Observation au microscope de la morphologie de bactéries...
> more
Mar 15, 2022
Le fonds Health for Life Capital II™ et les sociétés de son portefeuille ont connu une année 2021 exceptionnelle....
> more
Publications
Apr 11, 2022
Karima Relizani, Katy Le Corf, Camille Kropp, Rebeca Martin-Rosique, Déborah Kissi, Guillaume Déjean, Lisa...
> more
Feb 16, 2022
Samuel Bellais, Mélanie Nehlich, Maryne Ania, Aurore Duquenoy, Wilfrid Mazier, Ger van den Engh, Jan Baijer, Nicole...
> more
now on twitter
YSOPIA Bioscience

One possible strategy to increase the validity of precision psychiatry approaches in Bipolar disorders is to increa… t.co/q8D42xaal1

YSOPIA Bioscience © 2022 - all rights reserved terms and conditions Influa | Web Agency © 2018